OtherClinical Investigations (Human)
First clinical results for PSMA targeted alpha therapy using 225Ac-PSMA-I&T in advanced mCRPC patients
Mathias Johannes Zacherl, Franz Josef Gildehaus, Lena Mittlmeier, Guido Boening, Astrid Gosewisch, Vera Wenter, Nina-Sophie Schmidt-Hegemann, Claus Belka, Alexander Kretschmer, Jozefina Casuscelli, Christian G. Stief, Marcus Unterrainer, Peter Bartenstein, Andrei Todica and Harun Ilhan
Journal of Nuclear Medicine October 2020, jnumed.120.251017; DOI: https://doi.org/10.2967/jnumed.120.251017
Mathias Johannes Zacherl
1 Department of Nuclear Medicine, University Hospital, LMU Munich, Germany;
Franz Josef Gildehaus
1 Department of Nuclear Medicine, University Hospital, LMU Munich, Germany;
Lena Mittlmeier
1 Department of Nuclear Medicine, University Hospital, LMU Munich, Germany;
Guido Boening
1 Department of Nuclear Medicine, University Hospital, LMU Munich, Germany;
Astrid Gosewisch
1 Department of Nuclear Medicine, University Hospital, LMU Munich, Germany;
Vera Wenter
1 Department of Nuclear Medicine, University Hospital, LMU Munich, Germany;
Nina-Sophie Schmidt-Hegemann
2 Department of Radiation Oncology, University Hospital, LMU Munich, Germany;
Claus Belka
2 Department of Radiation Oncology, University Hospital, LMU Munich, Germany;
Alexander Kretschmer
3 Department of Urology, University Hospital, LMU Munich, Germany
Jozefina Casuscelli
3 Department of Urology, University Hospital, LMU Munich, Germany
Christian G. Stief
3 Department of Urology, University Hospital, LMU Munich, Germany
Marcus Unterrainer
1 Department of Nuclear Medicine, University Hospital, LMU Munich, Germany;
Peter Bartenstein
1 Department of Nuclear Medicine, University Hospital, LMU Munich, Germany;
Andrei Todica
1 Department of Nuclear Medicine, University Hospital, LMU Munich, Germany;
Harun Ilhan
1 Department of Nuclear Medicine, University Hospital, LMU Munich, Germany;
Data supplements
Supplemental Data
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 65, Issue 3
March 1, 2024
First clinical results for PSMA targeted alpha therapy using 225Ac-PSMA-I&T in advanced mCRPC patients
Mathias Johannes Zacherl, Franz Josef Gildehaus, Lena Mittlmeier, Guido Boening, Astrid Gosewisch, Vera Wenter, Nina-Sophie Schmidt-Hegemann, Claus Belka, Alexander Kretschmer, Jozefina Casuscelli, Christian G. Stief, Marcus Unterrainer, Peter Bartenstein, Andrei Todica, Harun Ilhan
Journal of Nuclear Medicine Oct 2020, jnumed.120.251017; DOI: 10.2967/jnumed.120.251017
First clinical results for PSMA targeted alpha therapy using 225Ac-PSMA-I&T in advanced mCRPC patients
Mathias Johannes Zacherl, Franz Josef Gildehaus, Lena Mittlmeier, Guido Boening, Astrid Gosewisch, Vera Wenter, Nina-Sophie Schmidt-Hegemann, Claus Belka, Alexander Kretschmer, Jozefina Casuscelli, Christian G. Stief, Marcus Unterrainer, Peter Bartenstein, Andrei Todica, Harun Ilhan
Journal of Nuclear Medicine Oct 2020, jnumed.120.251017; DOI: 10.2967/jnumed.120.251017
Jump to section
Related Articles
Cited By...
- Effectiveness of 225Ac-Labeled Anti-EGFR Radioimmunoconjugate in EGFR-Positive Kirsten Rat Sarcoma Viral Oncogene and BRAF Mutant Colorectal Cancer Models
- Current Status of Prostate-specific Membrane Antigen-targeted Alpha Radioligand Therapy in Prostate Cancer
- Development and Preclinical Evaluation of [211At]PSAt-3-Ga: An Inhibitor for Targeted {alpha}-Therapy of Prostate Cancer
- Clinical Experience with [225Ac]Ac-PSMA Treatment in Patients with [177Lu]Lu-PSMA-Refractory Metastatic Castration-Resistant Prostate Cancer
- Dual-Time-Point Posttherapy 177Lu-PSMA-617 SPECT/CT Describes the Uptake Kinetics of mCRPC Lesions and Prognosticates Patients Outcome
- Clinical Translation of Targeted {alpha}-Therapy: An Evolution or a Revolution?
- Clinical Translation of Targeted {alpha}-Therapy: An Evolution or a Revolution?
- Dosimetry in Radiopharmaceutical Therapy
- Prostate-Specific Membrane Antigen Radioligand Therapy Using 177Lu-PSMA I&T and 177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer: Comparison of Safety, Biodistribution, and Dosimetry
- Effects of 225Ac-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer: A Meta-Analysis
- An Improved 211At-Labeled Agent for PSMA-Targeted {alpha}-Therapy